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ABSTRACT
OBJECTIVES
To investigate the effectiveness of routine 
ultrasonography in the third trimester in reducing 
adverse perinatal outcomes in low risk pregnancies 
compared with usual care and the effect of this policy 
on maternal outcomes and obstetric interventions.
DESIGN
Pragmatic, multicentre, stepped wedge cluster 
randomised trial.
SETTING
60 midwifery practices in the Netherlands.
PARTICIPANTS
13 046 women aged 16 years or older with a low risk 
singleton pregnancy.
INTERVENTIONS
60 midwifery practices offered usual care (serial 
fundal height measurements with clinically indicated 
ultrasonography). After 3, 7, and 10 months, a third 
of the practices were randomised to the intervention 
strategy. As well as receiving usual care, women in 
the intervention strategy were offered two routine 
biometry scans at 28-30 and 34-36 weeks’ gestation. 
The same multidisciplinary protocol for detecting and 
managing fetal growth restriction was used in both 
strategies.
MAIN OUTCOME MEASURES
The primary outcome measure was a composite 
of severe adverse perinatal outcomes: perinatal 
death, Apgar score <4, impaired consciousness, 
asphyxia, seizures, assisted ventilation, septicaemia, 
meningitis, bronchopulmonary dysplasia, 
intraventricular haemorrhage, periventricular 
leucomalacia, or necrotising enterocolitis. Secondary 
outcomes were two composite measures of severe 
maternal morbidity, and spontaneous labour and 
birth.
RESULTS
Between 1 February 2015 and 29 February 2016, 60 
midwifery practices enrolled 13 520 women in mid-
pregnancy (mean 22.8 (SD 2.4) weeks’ gestation). 
13 046 women (intervention n=7067, usual care 
n=5979) with data based on the national Dutch 
perinatal registry or hospital records were included in 
the analyses. Small for gestational age at birth was 
significantly more often detected in the intervention 
group than in the usual care group (179 of 556 (32%) 
v 78 of 407 (19%), P<0.001). The incidence of severe 
adverse perinatal outcomes was 1.7% (n=118) for 
the intervention strategy and 1.8% (n=106) for usual 
care. After adjustment for confounders, the difference 
between the groups was not significant (odds ratio 
0.88, 95% confidence interval 0.70 to 1.20). The 
intervention strategy showed a higher incidence of 
induction of labour (1.16, 1.04 to 1.30) and a lower 
incidence of augmentation of labour (0.78, 0.71 
to 0.85). Maternal outcomes and other obstetric 
interventions did not differ between the strategies.
CONCLUSION
In low risk pregnancies, routine ultrasonography in 
the third trimester along with clinically indicated 
ultrasonography was associated with higher antenatal 
detection of small for gestational age fetuses but not 
with a reduced incidence of severe adverse perinatal 
outcomes compared with usual care alone. The 
findings do not support routine ultrasonography in the 
third trimester for low risk pregnancies.
TRIAL REGISTRATION
Netherlands Trial Register NTR4367.
Introduction
Fetal growth restriction, defined as failure to reach fetal 
growth potential, occurs in 7-10% of pregnancies.1  2 
Causes include smoking, exposure to teratogens, 
maternal malnutrition, infections, genetic and 
structural disorders, and placental insufficiency.3 Fetal 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Fetal growth restriction is a risk factor for perinatal mortality and morbidity and 
cardiovascular disease and neurodevelopmental disorders in adulthood
Routine ultrasonography in the third trimester detects neonates who are small 
for gestational age (SGA) significantly more often than usual care using serial 
fundal height measurements combined with clinically indicated ultrasonography
Evidence that routine ultrasonography in the third trimester reduces the 
incidence of severe adverse perinatal outcomes is lacking
WHAT THIS STUDY ADDS
In low risk pregnancies, routine ultrasonography in the third trimester combined 
with clinically indicated ultrasonography was associated with greater antenatal 
detection of SGA neonates and induction of labour but was not associated with a 
reduction in severe adverse perinatal outcomes compared with usual care 
Based on these findings, routine ultrasonography has no benefit (or harm) to the 
neonate but was associated with a moderately increased incidence of induction 
of labour
These findings do not support routine ultrasonography in the third trimester for 
low risk pregnancies
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growth restriction is a major risk factor for perinatal 
morbidity and perinatal death, including sudden 
intrauterine unexplained death.3-5 It is also associated 
with an increased risk of diseases in adulthood, 
such as neurodevelopmental and cardiovascular 
disorders.2  6 Monitoring fetal growth and managing 
suspected growth restriction are therefore key 
objectives of antenatal care.7 The terms fetal growth 
restriction and small for gestational age (SGA) are 
often used interchangeably although they do differ.3 
SGA is defined as the statistical deviation of fetal size 
or birth weight from a population based reference, 
with a predefined threshold that is usually the 10th 
centile.8 Antenatal SGA is indicated by fetal abdominal 
circumference or estimated fetal weight below the 10th 
centile.9 Because fetal growth restriction is not easily 
measured but most often occurs in SGA fetuses,10 SGA 
is generally used as a proxy for growth restriction. 
Because many SGA infants can be constitutionally 
small but healthy, this proxy is unsatisfactory.11 To 
improve the detection of fetal growth restriction 
prenatally, repeated measurements of fetal growth are 
recommended.12-14
Which third trimester screening strategy is most 
effective in detecting fetal growth restriction is 
controversial.11 15 Routine ultrasonography in the 
third trimester detects SGA at birth more often than 
usual care, which comprises serial fundal height 
measurements combined with clinically indicated 
ultrasonography. Sensitivities of routine third trimester 
ultrasonography range from 22% to 57%.9  11  16 
Nevertheless, evidence based guidelines in many 
Western countries, including the Netherlands, do 
not recommend routine biometry scans in the third 
trimester because in previous clinical trials perinatal 
outcomes were not positively affected.7 14 15 17 18 Also, 
when evaluating the introduction of a new screening 
programme, adverse effects, such as unnecessary 
medical care, should be considered.19 Major limitations, 
however, have been identified in earlier trials.15 Firstly, 
almost all trials were underpowered to detect clinically 
significant differences in severe perinatal outcomes. 
Secondly, in many trials, only the ultrasound screening 
strategy was described and the subsequent clinical 
management of suspected fetal growth restriction 
was unclear.15 Biometry screening alone cannot 
prevent adverse perinatal outcomes unless screening 
is combined with effective clinical management.11 
Thirdly, the ultrasound technology used in most of the 
earlier randomised studies is outdated.15
The Dutch Ministry of Health considered introducing 
routine ultrasonography in the third trimester of 
pregnancy but was unable to decide on the effectiveness 
of this screening approach owing to lack of evidence. We 
therefore conducted a large pragmatic trial, the IUGR 
Risk Selection (IRIS) study, to evaluate the effects of 
offering routine ultrasonography in the third trimester 
to low risk pregnant women in the Netherlands. For 
this trial, we developed a multidisciplinary protocol 
based on consensus for detecting and managing 
suspected fetal growth restriction.13 We chose a 
cluster randomised design to roll-out the intervention 
and to avoid contamination bias due to the women’s 
preferences for or against ultrasound scans.20 The 
stepped wedge design facilitated the participation of a 
large number of midwifery practices, even if they had 
a preference for one of the screening strategies. With 
this design, each practice first applied usual care and 
then switched to offering routine ultrasonography 
in the third trimester at a defined moment during 
the study, depending on the randomisation scheme. 
In this stepped wedge cluster randomised trial we 
evaluated the effectiveness of routine ultrasonography 
in the third trimester combined with usual care (ie, 
serial fundal height measurements with clinically 
indicated ultrasonography) in reducing severe adverse 
perinatal outcomes in low risk pregnancies compared 
with usual care alone. Both approaches included a 
multidisciplinary protocol for detecting and treating 
fetal growth restriction. We also examined the effect of 
the intervention on maternal outcomes and obstetric 
interventions.
Methods
Study design and participants
The IRIS study was a nationwide, stepped wedge 
cluster randomised trial conducted in 60 primary 
care midwifery practices in the Netherlands in low 
risk pregnant women. The study design has been 
previously described.20
In the Netherlands, hospitals provide secondary 
and tertiary antenatal care, whereas primary care 
midwives are independent medical practitioners 
qualified to provide full maternity care for women 
with uncomplicated low risk pregnancies.21 Midwifery 
practices were invited to participate in the IRIS study 
at meetings, at postgraduate courses, and through 
social media and professional journals.20 Practices were 
included if the midwives had completed the postgraduate 
registration training in the detection of fetal growth 
restriction based on the guideline of the Royal Dutch 
Association of Midwives (KNOV).17 Biometry scans 
were performed in sonography centres or in midwifery 
practices. Some sonographers worked in both primary 
care centres and hospitals and others worked in primary 
care only. Participating practices signed an agreement 
showing their commitment to the study protocol.
Sonographers conducted third trimester biometry 
according to the guidelines of the Dutch Society of 
Obstetrics and Gynaecology (NVOG).22 23 Sonographers 
who participated in the IRIS study were experienced 
in performing biometry and held a certificate for 
structural anomaly screening (73% of 154 participating 
sonographers) or passed a biometry quality test before 
the trial (27%), based on four biometry scans assessed 
by two experienced sonographers; had successfully 
completed a module on fetal biometry from a national 
Dutch medical e-learning education programme (see 
www.medicaleducation.nl); and used ultrasound 
equipment according to the standards of the Dutch 
Society of Obstetrics and Gynaecology.14 Two 
independent and experienced sonographers who were 
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board members of the Dutch Professional Organisation 
of Sonographers carried out quality assessments of the 
sonographers during the trial.
From 1 February 2015 to 29 February 2016, pregnant 
women in the participating midwifery practices who 
fulfilled the inclusion criteria were informed about 
the study and given a trial information leaflet by 
their midwife during the first consultation. After the 
20 week anomaly screening had been conducted if 
desired, the women were invited to take part in the 
study. Inclusion criteria for women with a low risk 
pregnancy were: antenatal care in a participating 
midwifery practice at enrolment, age 16 years or older, 
a singleton pregnancy, no major obstetric or medical 
risk factors, and a reliable expected date of delivery 
based on a dating scan or a reliable first day of the 
last menstrual period.14 Participants provided written 
informed consent for data usage.
The control strategy (usual care) comprised 
fetal growth monitored by serial fundal height 
measurements and ultrasonography if clinically 
indicated. In addition to their usual care, women in the 
intervention strategy received two biometry ultrasound 
scans in the third trimester, at 28-30 and 34-36 weeks’ 
gestation, to detect fetal growth restriction.
Randomisation and masking
Midwifery practices formed the unit of cluster 
randomisation. At the onset of data collection on 1 
February 2015 all the midwifery practices (n=60) 
carried out the control strategy, with a third sequentially 
crossing over to the intervention strategy at 3, 7, and 
10 months (fig 1). Practices were stratified before 
randomisation into large and small practices, with 
the median practice size (300 women annually) as a 
cut-off. A stratified computer generated randomisation 
sequence determined the order in which practices 
changed from the control to intervention strategy. An 
independent statistician performed randomisation on 
anonymous data from the midwifery practices. Because 
of the nature of the intervention, it was not possible to 
blind participants, care providers, and researchers to 
group allocation.
Procedure
The logistics of the study and enrolment procedures 
were piloted in January 2015. The pilot data were 
not included in the analyses. In the intervention and 
control strategies, we used prenatal SGA and slow 
fetal abdominal growth as indicators for suspected 
fetal growth restriction. We defined prenatal SGA 
as a fetal abdominal circumference below the 10th 
centile based on a population based Dutch reference 
growth curve.24 Slow fetal abdominal growth was 
defined as a decrease in abdominal circumference of 
at least 20 centiles (eg, from the 70th to 50th centile, 
with a minimum interval of two weeks) on the Dutch 
reference curve.13 24 A volume of amniotic fluid of less 
than 2 cm in the deepest vertical pocket was also an 
indication of suspected fetal growth restriction. In 
both strategies, women with suspected fetal growth 
restriction were referred to obstetrician led care for 
further diagnosis and management. Women remained 
in the strategy that their midwifery practice was 
allocated to on enrolment. In both strategies, women 
with suspected fetal growth restriction were referred 
to obstetrician led care for further diagnosis and 
management. Suspected fetal growth restriction was 
detected and managed based on a protocol specifically 
developed for this study in a Delphi study incorporating 
recommendations from national and international 
guidelines (see appendix 1).13 14 17 25
Information on the characteristics of the participating 
midwifery practices was collected by electronic survey 
before the start of the study in January 2015. At 
inclusion in the study, women completed a survey of 
questions on personal characteristics, anthropometric 
measurements, smoking status, and intake of alcohol 
and recreational drugs.
We retrieved clinical data on care processes, 
perinatal outcomes, and maternal outcomes from 
the database of the Netherlands Perinatal Registry 
(Perined), which collects healthcare data from midwife 
led and obstetrician led care in the Netherlands.26 Data 
on ultrasound scans were obtained from the databases 
of the midwifery practices and the participating 
sonography centres.
For suspected severe adverse perinatal outcomes 
based on the Perined database, five trained research 
assistants retrieved detailed clinical data from hospital 
files using standard case report forms. Hospital files 
were selected in cases of perinatal death, a low Apgar 
score (<4) at five minutes, a birth weight less than the 
2.3rd centile,27 (or a birth weight between the 2.3rd and 
20†
20
20
No of
practices
1039
1059
980
1 Feb to
30 Apr 2015
1568
1184
1061
1 May to
31 Aug 2015*
1142
1061
825
1 Sep to
30 Nov 2015
1225
1230
1146
1 Dec 2015 to
29 Feb 2016
Intervention strategy (n=7372) Control strategy (n=6148)
Fig 1 | Study sample in stepped wedge cluster randomised trial, showing numbers recruited in each cluster and 
period. *Crossover postponed after one month because of fewer than expected inclusions †One midwifery practice 
dropped out in April 2015, after the first randomisation
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5th centile and) neonatal admission for more than three 
days, and referral to a neonatologist if the admission 
data were missing or were not clearly registered in 
Perined. To warrant adequate retrieval of information 
from the neonatal records by the research assistants, 
an experienced neonatologist helped to operationalise 
the perinatal outcomes, collected using the standard 
case report forms.
Outcomes
The primary outcome was a dichotomous composite 
measure of 12 adverse perinatal outcomes occurring 
up to seven days after birth: perinatal death between 
28 weeks’ gestation and seven days after birth; Apgar 
score <4 at five minutes; impaired consciousness (coma, 
stupor, or decreased response to pain); asphyxia, 
with arterial base excess of cord blood less than −12 
mmol/L; seizures on at least two occasions within 72 
hours of birth; assisted ventilation by endotracheal 
tube for more than 24 hours started within 72 hours 
of birth; septicaemia confirmed by blood culture; 
meningitis confirmed by culture of cerebrospinal fluid; 
bronchopulmonary dysplasia requiring oxygen after 
36 weeks’ gestation and confirmed by radiography; 
intraventricular haemorrhage grade 3 or 4 confirmed 
by ultrasonography or autopsy; cystic periventricular 
leucomalacia confirmed by ultrasonography; or 
necrotising enterocolitis confirmed by radiography, 
surgery, or autopsy.
Secondary neonatal outcomes were congenital 
abnormalities, birth weight, gestational age, 
prematurity (<37 weeks’ gestation), SGA at birth (birth 
weight <10th centile), large for gestational age (birth 
weight >90th centile),27 and neonatal mortality from 
eight to 28 days after birth.
Two dichotomous maternal composite outcomes 
were defined as secondary outcomes. The first 
composite outcome was at least one of four maternal 
adverse peripartum outcomes: maternal death 
within 42 days of birth, hypertensive disorders or 
pre-eclampsia (diastolic blood pressure ≥95 mm 
Hg with or without proteinuria, or ≥90 mm Hg with 
proteinuria), postpartum haemorrhage of 1000 mL or 
more, or anal sphincter damage. The second composite 
outcome was spontaneous labour and birth, defined 
as a spontaneous vaginal birth with no induction 
or augmentation of labour, no drug pain relief, no 
vacuum or forceps assisted birth, and no caesarean 
section. Other secondary outcomes were the individual 
components of the perinatal and maternal composite 
outcomes and the secondary outcomes non-cephalic 
presentation at the start of labour in midwife led care 
and birth in midwife led or obstetrician led care.
Statistical analysis
Perined data suggested an incidence of 1.54% for the 
severe adverse perinatal composite outcome in low 
risk pregnant women in the Netherlands. We defined 
a clinically significant reduction of severe adverse 
perinatal outcome in the intervention strategy as 
1.54% to 1.0%. With an α of 5% and 80% power, 
inclusion of 13 536 women was required. Assuming an 
intracluster correlation coefficient of 0.0003 based on 
previous literature,28 and an a priori assumed average 
cluster size (ie, practice size of 250 women annually), 
we aimed to include 15 000 pregnant women (7500 
for each strategy) to be able to take possible clustering 
effects into account.20
We performed double entry analyses in a 5% sample 
of the hospital record forms collected. Based on the 
hospital records, we also calculated the number of 
women who received additional ultrasound and 
Doppler scans in obstetrician led care after they were 
referred for suspected fetal growth restriction by 
midwives because of fetal abdominal circumference 
below the 10th centile or slow fetal abdominal growth.
To estimate the diagnostic accuracy of the two 
third trimester screening strategies to detect SGA at 
birth (birth weight <10th centile based on the Dutch 
reference curve),27 we calculated sensitivity, specificity, 
and positive and negative predictive values of fetal 
abdominal circumference below the 10th centile, slow 
fetal abdominal growth, or a combination of the two.29 
We compared sensitivity and specificity rates between 
the intervention and control strategies using the χ2 test 
and between the scans at 28-30 weeks’ gestation and 
34-36 weeks’ gestation in the intervention strategy 
using the McNemar test.
As a first step, we conducted univariable logistic 
regression analyses to see if routine ultrasonography 
in the third trimester was associated with a reduction 
in severe adverse perinatal outcomes and adverse 
secondary neonatal and maternal outcomes. Then we 
conducted multilevel multivariable logistic regression 
analyses for the dichotomous primary and secondary 
outcomes. For continuous secondary outcomes, we 
ran multivariable linear mixed models. Because of the 
cluster randomised design, we included midwifery 
practice as a random effect in the multilevel regression 
models. Time of inclusion, divided into four groups 
according to the crossover from usual care to the 
intervention strategy, was considered as a fixed factor. 
As the study condition (intervention versus usual 
care) and time of inclusion were strongly correlated 
(Pearson’s r=0.73, P<0.001), indicating collinearity,30 
we did not include this fixed factor in the multilevel 
multivariable logistic (or linear) regression analyses. 
Also, we adjusted our main analyses for potential 
confounders selected a priori and based on previous 
literature: maternal age; body mass index; smoking, 
alcohol, or recreational drug use; parity; educational 
level; employment status; marital status; infant’s 
sex; and size of the midwifery practice (≤300 or >300 
women annually).31 32 Analyses were performed on 
complete case analysis given that less than 5% of the 
data on confounders were missing. We performed 
a multilevel analysis only if the expected number 
of events per cluster was at least one, as advocated 
previously.33 We used an intention to treat approach. 
We then conducted a fully adjusted post hoc sensitivity 
analysis for the primary outcome, comparing women 
in the intervention strategy, who received two routine 
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ultrasound scans, with women in the control strategy, 
who received no ultrasound scan. Neonates born before 
the second routine ultrasound scan were excluded from 
the additional analysis. We set the level of significance 
at P<0.05. Statistical analyses were performed with the 
Statistical Package for Social Science (SPPS V.22; IBM, 
Chicago, IL) and R (V.3.4.3).
Patient and public involvement
A patient representative was a member of the project 
group that drafted the grant proposal and design of the 
IRIS study and of the sounding board of the IRIS study 
providing feedback to design aspects and discussing 
study results. Client organisations will be involved in 
communicating the findings of the study to the general 
public.
Results
From 1 February 2015, 60 midwifery practices 
participated in the IRIS study (about 12% of practices 
in the Netherlands). Nineteen practices performed 
biometry scans and the others referred women to one of 
the 18 sonography centres involved in the study. After 
the first randomisation in April 2015, one midwifery 
practice withdrew from the study because of time 
constraints. The remaining 59 practices participated in 
the study until 29 February 2016. As recruitment was 
slower than anticipated, the predefined recruitment 
period of one year was extended, and hence the 
second group of midwifery practices crossed over to 
the intervention strategy one month later than planned 
(fig 1). Twenty practices provided the intervention in 
the second period (May to August 2015), 40 in the 
third period (September to November 2016), and 59 in 
the fourth period (December 2015 to February 2016) 
(fig 1).
A total of 14 323 pregnant women were invited 
to participate in the IRIS study (fig 2). Six women 
did not fulfil the inclusion criteria and 797 refused 
to participate. The remaining 13 520 women were 
enrolled in mid-pregnancy (mean 22.8 (SD 2.4) weeks’ 
gestation) and provided baseline characteristics. 
Neonates of the participating women were born 
between June 2015 and August 2016. Data from 
13 024 (96.3%) women and neonates were linked to 
data in the Perined database. Data were retrieved from 
hospital records for 2339 cases, selected for additional 
in-depth data collection. In total, 13 046 women with 
Perined data or data from hospital records, or both 
were included in one or more analyses, with 5979 
women in the usual care strategy and 7067 women 
in the intervention strategy. Data on severe adverse 
perinatal outcomes were available for 12 993 of 13 046 
(99.6%) women, 7040 in the intervention strategy and 
5953 in the control strategy (fig 2).
Double entry analyses on hospital case report forms 
of 111 women were carried out. The overall incidence 
of error in data entry was 3.2% (2.6% for neonatal data 
and 3.7% for maternal data). 
Table 1 shows the baseline characteristics of the 
participating midwifery practices. Table 2 shows the 
personal and clinical baseline characteristics of the 
participants. Women in the intervention strategy had 
significantly more ultrasound scans than women in the 
control strategy (mean 2.04 (SD 0.75) v 0.88 (0.96), 
P<0.001). For the indication biometry, the values were 
lower (mean 1.84 (0.82) v 0.72 (0.90), respectively, 
P<0.001). Of 5840 women (82.6% of 7067 women) 
in the intervention strategy, who were not referred to 
obstetrician led care before 37 weeks’ gestation, 3.0% 
(n=177) did not receive a third trimester ultrasound 
scan. These 5840 non-referred pregnant women had a 
mean number of 1.91 (SD 0.8) scans for the indication 
biometry. Routine ultrasound scans were performed 
at mean gestational ages of 28.9 (SD 0.6) and 34.7 
(SD 0.6) weeks. Of 5049 women (84.4% of 5979 
women) receiving usual care, who were not referred to 
obstetrician led care before 37 weeks’ gestation, 41.0% 
(n=2072) did not receive a third trimester ultrasound 
scan.
Data from hospital files on fetuses with a suspected 
severe adverse perinatal outcome were used to 
analyse the level of adherence to the multidisciplinary 
protocol for diagnosing and managing fetal growth 
restriction. Of the pregnant women (n=107) referred 
to obstetrician led care because of a fetal abdominal 
circumference below the 10th centile, 97% (74 of 76) 
in the intervention strategy had additional ultrasound 
scans compared with 97% (30 of 31 women) receiving 
usual care. For 103 of these 107 women, 97% (71 of 
73) in the intervention strategy and 87% (26 of 30) in 
the usual care group had Doppler scans. For women 
referred for slow fetal abdominal growth (n=162), 91% 
(112 of 123) in the intervention strategy had additional 
ultrasounds compared with 90% (35 of 39) in the 
usual care strategy. For 132 of 162 women referred for 
slow fetal abdominal growth, 78% (78 of 100) in the 
intervention strategy and 72% (23 of 32) in the usual 
care strategy had Doppler scans. None of these results 
was significantly different between the two strategies.
Table 3 shows the diagnostic accuracy for detecting 
SGA at birth (birth weight <10th centile) for both 
screening strategies. In the intervention strategy, more 
SGA neonates (22%) had an abdominal circumference 
below the 10th centile compared with SGA neonates 
in the usual care strategy (13%; P<0.001). Also, in the 
intervention strategy, significantly more SGA neonates 
(32%) had an abdominal circumference below the 
10th centile or slow fetal growth compared with SGA 
neonates in the usual care strategy (19%; P<0.001) 
and specificity differed significantly (90% and 97%, 
respectively; P<0.001) (table 3).
The overall incidence of a severe adverse perinatal 
composite outcome was 1.7% (n=224); 1.7% 
(n=118) for the intervention strategy and 1.8% 
(n=106) for the usual care strategy (table 4). In a 
multilevel multivariable logistic regression analysis, 
routine ultrasonography in the third trimester was 
not associated with a significant reduction in severe 
adverse perinatal composite outcome (adjusted odds 
ratio 0.88, 95% confidence interval 0.70 to 1.20). The 
post hoc sensitivity analysis showed similar results 
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(0.83, 0.59 to 1.34). Secondary neonatal outcomes 
were also not significantly different between the 
two strategies. No significant differences were found 
in maternal morbidity and mortality between the 
groups (table 5). In a multilevel multivariable logistic 
regression analysis, routine ultrasonography in the 
third trimester was not related to the composite 
outcome of maternal peripartum morbidity or mortality 
(1.06, 0.95 to 1.18), or spontaneous labour and birth 
(1.00, 0.92 to 1.08). Routine ultrasonography in 
the third trimester was not associated with medical 
interventions in the peripartum period, with two 
exceptions (table 5). In a multilevel multivariable 
logistic regression adjusted for confounders, routine 
ultrasonography in the third trimester was associated 
with a higher incidence of induction of labour (1.16, 
1.04 to 1.30) and a lower incidence of augmentation of 
labour (0.78, 0.71 to 0.85). Although higher numbers 
of births were observed in obstetrician led care in 
the intervention strategy compared with usual care 
strategy (65.0% v 63.3%; table 5), this association 
was not significant in a multilevel multivariable 
logistic regression adjusted for confounders (1.05, 
0.96 to 1.14).
Available data on severe
adverse perinatal outcomes
No severe adverse perinatal outcome
Severe adverse perinatal outcome
Missing outcome data
5847
106
26
Included in one or more of the primary analyses Included in one or more of the primary analyses
5979
Available data on severe
adverse perinatal outcomes
No severe adverse perinatal outcome
Severe adverse perinatal outcome
Missing outcome data
6922
118
27
7067
Midwifery practices
Women randomised in stepped wedge cluster
Excluded
Not meeting inclusion criteria
Declined use of medical data
3
344
Women providing baseline characteristics
Selected for collection of hospital data1308
Women allocated to control strategy
14 323
60*
347
Failed linkage to or missing
  Perined data
Failed linkage to both Perined
  and hospital data†
176
169
Failed linkage to or missing
  Perined data
Failed linkage to both Perined
  and hospital data†
320
305
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Fig 2 | Flow chart of IRIS study. *One midwifery practice withdrew from the study before crossover to the intervention 
strategy (59 practices participated in the study). †For 22 women (ie, 15 women in the intervention strategy and seven 
women in the control strategy) with missing data in the Perined database, data were available from hospital records
Table 1 | Characteristics of participating midwifery practices
Characteristics Total (n=59)*
Start date of intervention strategy
1 May 2015 (n=19)* 1 September 2015 (n=20) 1 December 2015 (n=20)
Mean (SD) No of midwives per practice 5.0 (2.0) 5.2 (2.1) 5.0 (2.4) 4.9 (1.7)
Ultrasound biometry in midwifery practice (No (%)) 19 (32) 9 (47) 3 (15) 7 (35)
Ultrasound biometry in sonography centre (No (%)) 40 (68) 10 (53) 7 (85) /13 (65)
Mean (SD) No of women in 2013 422.2 (226.0) 400.3 (155.0) 421.1 (252.3) 444.1 (261.7)
Mean (SD) nulliparous women (%) 46.7 (9.0) 44.7 (11.5) 46.9 (7.3) 48.4 (7.4)
Mean (SD) antepartum referrals to hospital care in 2013 (%) 37.5 (11.5) 37.1 (12.1) 37.8 (8.7) 37.6 (13.7)
Median (interquartile range) birth in midwife led care in 2013 88.0 (57.0; 128.0) 83.0 (58.0; 118.0) 87.5 (59.3; 128.3) 95.5 (52.5; 139.3)
Mean (SD) home births among midwife led births in 2013 (%) 49.3 (20.2) 49.6 (17.6) 52.4 (22.1) 45.9 (20.8)
Customised fundal height charts† (No (%)) 27 (46) 9 (47) 6 (30) 12 (60)
*One practice dropped out in April 2015. 
†None reported use of non-customised charts for fundal height measurements.
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Discussion
In this large, pragmatic, nationwide, stepped wedge 
cluster randomised trial in low risk pregnant women, using 
a multidisciplinary protocol for detecting and managing 
fetal growth restriction, routine ultrasonography in the 
third trimester improved prenatal detection of neonates 
who were small for gestational age (SGA) compared 
with usual care. But this approach did not result in a 
significantly lower incidence of severe adverse perinatal 
outcomes. Routine ultrasonography was not associated 
with significantly improved secondary neonatal 
outcomes or secondary maternal composite peripartum 
outcomes. Routine ultrasonography was associated with 
a higher incidence of induction of labour.
Table 2 | Personal and baseline characteristics of participants. Data are numbers (percentages) unless stated otherwise
Characteristics* Intervention strategy (n=7067) Control strategy (n=5979) Total (n=13 046)
Parity:
 Nulliparous 3368 (47.7) 2928 (49.0) 6296 (48.3)
 Multiparous 3632 (51.4) 3004 (50.2) 6636 (50.9)
 Missing 67 (0.9) 47 (0.8) 114 (0.9)
Mean (SD) maternal age (years) 31.0 (4.5) 31.0 (4.3) 31.0 (4.4)
Body mass index:
 <18.5 232 (3.3) 185 (3.1) 417 (3.2)
 18.5-25.0 4583 (64.9) 4025 (67.3) 8608 (66.0)
 >25.0 2149 (30.4) 1707 (28.5) 3856 (29.6)
 Missing 103 (1.5) 62 (1.0) 165 (1.3)
Ethnicity:
 Dutch 5096 (72.1) 4684 (78.4) 9780 (75.0)
 Other Western 766 (10.8) 576 (9.6) 1342 (10.3)
 Non-Western 1202 (17.0) 714 (11.9) 1916 (14.7)
 Missing 3 (0.0) 5 (0.1) 8 (0.1)
Education:
 High 3770 (53.3) 3190 (53.4) 6960 (53.3)
 Medium 2450 (34.7) 2115 (35.4) 4565 (35.0)
 Low 700 (9.9) 588 (9.8) 1288 (9.9)
 Missing 147 (2.1) 86 (1.4) 233 (1.8)
Work status:
 Employed 5763 (81.5) 5043 (84.3) 10 806 (82.8)
 Unemployed 1188 (16.8) 863 (14.4) 2051 (15.7)
 Missing 116 (1.6) 73 (1.2) 189 (1.4)
Marital status:
 Married or cohabiting 6457 (91.4) 5604 (93.7) 12 061 (92.4)
 Not cohabiting 352 (5.0) 198 (3.3) 550 (4.2)
 Single 167 (2.4) 121 (2.0) 288 (2.2)
 Missing 91 (1.3) 56 (0.9) 147 (1.1)
Maternal smoking, alcohol use, or recreational drug use:
 Yes 2283 (32.3) 1956 (32.7) 4239 (32.5)
 No 4759 (67.3) 4004 (67.0) 8763 (67.2)
 Missing 25 (0.4) 19 (0.3) 44 (0.3)
Smoking during pregnancy:
 Yes 1003 (14.2) 835 (14.0) 1838 (14.1)
 No 6048 (85.6) 5129 (85.8) 11 177 (85.7)
 Missing 16 (0.2) 15 (0.2) 31 (0.2)
Alcohol consumption during pregnancy:
 Yes 1679 (23.8) 1481 (24.8) 3160 (24.2)
 No 5362 (75.9) 4482 (75.0) 9844 (75.5)
 Missing 26 (0.4) 16 (0.3) 42 (0.3)
Recreational drug use during pregnancy:
 Yes 86 (1.2) 70 (1.2) 156 (1.2)
 No 6963 (98.5) 5896 (98.6) 12 859 (98.6)
 Missing 18 (0.3) 13 (0.2) 31 (0.2)
Medical indication for fetal ultrasound determined at inclusion:
 Yes 1324 (18.7) 1121 (18.7) 2445 (18.7)
 No 5743 (81.3) 4858 (81.3) 10 601 (81.3)
Type of medical indications determined at inclusion:
 Fundal height measurements unreliable* 137 (1.9) 119 (2.0) 256 (2.0)
 Previous SGA neonate* 176 (2.5) 161 (2.7) 337 (2.6)
 Other (not biometry related) indication† 1012 (14.3) 844 (14.1) 1856 (14.2)
Fetal sex:
 Female 3480 (49.2) 2923 (48.7) 6403 (48.9)
 Male 3585 (50.7) 3055 (50.9) 6640 (50.9)
 Missing 2 (0) 1 (0) 3 (0)
SGA=small for gestational age (birth weight <10th centile according to Dutch birth weight curve).27
*Percentages do not always add up to 100% because of combinations of multiple medical indications for ultrasonography in one pregnancy.
†Other clinical indications for ultrasonography.
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Comparison with other studies
Our trial addressed important shortcomings of 
previous studies.15 Modern ultrasound equipment 
was used, sonographers met predefined quality 
criteria, and a multidisciplinary protocol was applied. 
Nevertheless, our findings are in line with a previous 
meta-analysis, which failed to show better perinatal 
outcomes in women who received routine ultrasound 
scans after 24 weeks’ gestation, based on 13 previous 
trials (n=34 980).15
Possible explanations for our findings are: routine 
ultrasound fetal biometry is ineffective in detecting 
fetal growth restriction and preventing subsequent 
adverse outcomes in low risk pregnancies; adding 
routine ultrasound scans in the third trimester 
to usual care does not yield major benefits 
because women receiving such care already 
undergo one clinically indicated ultrasound scan 
on average in the third trimester; the quality of 
ultrasonography was insufficient; and using fetal 
abdominal circumference below the 10th centile 
(in combination with biometric measures of slow 
growth) on a population based curve is ineffective 
in detecting fetal growth restriction, and better 
methods are required.
The number of babies with a birth weight below the 
10th centile was around 8% in our study. Previous 
research suggests that most of these babies are likely 
to be constitutionally small rather than growth 
restricted and would not be at increased risk of severe 
adverse perinatal outcomes.11 Women assigned to 
the usual care strategy had one clinically indicated 
ultrasound scan on average in the third trimester of 
pregnancy. Moreover, nearly one in five women in 
the intervention and usual care strategies had an 
indication for an ultrasound scan in the third trimester 
that was identified at inclusion in the study. Routine 
antenatal ultrasonography might therefore have little 
or no added benefit in detecting SGA neonates at risk of 
adverse outcomes compared with clinically indicated 
ultrasonography as part of usual care in the third 
trimester.
Another explanation for our findings might be that 
the quality of ultrasound scans was too low. Similar 
to the Pregnancy Outcome Prediction (POP) study, 
we found that sensitivity rates were higher for the 
intervention strategy with routine ultrasonography 
compared with usual care strategy with clinically 
indicated ultrasonography, although specificity rates 
were lower.11 Thus our findings suggest that repeated 
ultrasonography measures increase the detection of 
SGA but are also accompanied by higher false positive 
rates. In the intervention strategy, for an abdominal 
circumference below the 10th centile or slow growth 
in abdominal circumference the sensitivity in detecting 
birth weight below the 10th centile was 32% and 
Table 3 | Diagnostic accuracy of two screening strategies with small for gestational age (SGA) at birth as outcome
Ultrasound variables
Intervention strategy 
(n=6909)
Control strategy 
(n=5498)
Routine fetal biometry at 
28-30 weeks’ gestation 
(n=6909)*
Routine fetal biometry at 
34-36 weeks’ gestation 
(n=6888)*
SGA 
(n=556)
No SGA 
(n=6353)
SGA 
(n=407)
No SGA 
(n=5091)
SGA 
(n=556)
No SGA 
(n=6353)
SGA 
(n=554)
No SGA 
(n=6334)
Total (No)
AC <P10 or slow growth 179 651 78 153 — — — —
AC <P10 122 156 53 60 74 126 63 44
Slow growth 76 522 34 100 — — — —
Sensitivity (% (95% CI))
AC <P10 or slow growth 32 (28 to 36) 19 (15 to 23)† — — — —
AC <P10 22 (19 to 26) 13 (10 to 17)† 13 (11 to 16) 11 (9 to 14)‡
Slow growth 14 (11 to 17) 8 (6 to 11)† — — — —
Specificity (% (95% CI))
AC <P10 or slow growth 90 (89 to 91) 97 (96 to 97)† — — — —
AC <P10 98 (97 to 98) 99 (98 to 99)† 98 (97 to 98) 99 (99 to 100)§
Slow growth 92 (91 to 93) 98 (97 to 98)† — — — —
Positive predictive value (% (95% CI))
AC <P10 or slow growth 22 (19 to 24) 34 (28 to 40) — — — —
AC <P10 44 (39 to 49) 47 (38 to 56) 37 (31 to 44) 59 (50 to 68)
Slow growth 13 (10 to 15) 25 (19 to 33) — — — —
Negative predictive value (% (95% CI))
AC <P10 or slow growth 94 (93 to 94) 94 (93 to 94) — — — —
AC <P10 93 (93 to 94) 93 (93 to 94) 93 (92 to 93) 93 (92 to 93)
Slow growth 92 (92 to 93) 93 (92 to 93) — — — —
For diagnostic accuracy analyses, 639 cases with incomplete data on third trimester ultrasound scans were excluded. Intervention strategy=prenatal 
screening for fetal growth restriction based on routine biometry scans in third trimester in combination with serial fundal height measurements and 
ultrasonography if clinically indicated. Control strategy=prenatal screening for fetal growth restriction based on serial fundal height measurements and 
ultrasonography only if clinically indicated.
SGA=small for gestational age (birth weight <10th centile (<P10) of Dutch national (Perined) birth weight curve27); AC <P10=abdominal circumference 
estimated by fetal biometry scan <P10 on Dutch growth curve24; slow growth=decrease of ≥20 centiles of abdominal circumference on Dutch growth 
curve with interval of at least two weeks from gestational age ≥26 weeks and 0 days.13
*Numbers for routine biometry scans at 28-30 weeks’ gestation and at 34-36 weeks’ gestation differ slightly because of missing values.
†χ2 tests showed that sensitivities of AC <P10 or slow growth (P<0.001), AC <P10 (P<0.001), and slow growth (P=0.010) were significantly higher in the 
intervention strategy than in the control strategy, whereas specificities of these measures were significantly higher in the control strategy (all P<0.001).
‡A McNemar test revealed no differences in sensitivity between the fetal biometry scan at 28-30 weeks’ gestation and 34-36 weeks’ gestation (P=0.38).
§A McNemar test showed a higher specificity of the fetal biometry scan at 34-36 weeks’ gestation compared with the scan at 28-30 weeks’ gestation 
(P<0.001).
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the positive predictive value was 22%. The positive 
predictive value of an abdominal circumference 
below the 10th centile was higher for the second 
routine scan (59%) at 34-36 weeks’ gestation than 
for the first scan at 28-30 weeks’ gestation (37%), 
whereas negative predictive values were similar, in 
line with the findings of the POP study.11 Thus late 
third trimester scans seem to have more diagnostic 
accuracy than earlier ones. Also, sensitivity was 22% 
for an abdominal circumference below the 10th centile 
in the intervention strategy, similar to the findings of 
a large nationwide French population based study 
(n=14 100).9 Single centre studies with smaller sample 
sizes, however, showed better accuracy, which might be 
because a limited number of dedicated sonographers 
performed the ultrasound scans.11 16 Sensitivity and 
specificity rates vary with the prevalence of disease.34 
As our study was conducted in a low risk population, 
a lower sensitivity and higher specificity might be 
expected than in the general population. Although 
the accuracy of ultrasonography in detecting low 
birth weight is higher than that of fundal height 
measurement, systematic errors in the prediction of 
SGA neonates using fetal abdominal circumference 
or estimated fetal weight limit its accuracy because 
these predictions are based on an estimation with an 
algorithm.35 Nevertheless, even if not used routinely, 
fetal biometry is frequently performed. Although 
quality assurance systems have been developed for 
the anomaly scan, much less attention is paid to 
developing systems to guarantee the quality of fetal 
biometry in the third trimester.36 Given that low birth 
weight is associated with adverse perinatal outcomes, 
the quality of fetal biometry should be maintained to 
the highest standard.
Even if the quality of ultrasonography is improved, 
the most appropriate screening test for fetal growth 
restriction is not clear. The centiles for measurements 
of fetal biometry, estimated fetal weight and birth 
weight, depend on the charts used. Some growth charts 
are universal and prescriptive, which means they show 
optimal growth in a healthy population, whereas 
others are customised for maternal characteristics, 
such as parity and ethnicity. So far, a consensus on 
the best charts for fetal growth and birth weight has 
not been reached.37 A recent large retrospective study 
Table 4 | Severe adverse perinatal (composite) outcome and secondary neonatal outcomes
Perinatal and neonatal outcomes Total No*
No, No of events (%) Odds ratio  
(95% CI) or  
P value†
Adjusted odds ratios 
or β linear regression 
coefficient (95% CI)‡
Intervention 
strategy
Control  
strategy
Severe adverse perinatal outcome
Composite of severe adverse perinatal outcome§ 12 993 7040, 118 (1.7) 5953, 106 (1.8) 0.94 (0.72 to 1.23) 0.88 (0.70 to 1.20)
Perinatal death, 28 weeks’ gestational age to 7 days postnatal: 13 043 7066, 14 (0.2) 5977, 15 (0.3) 0.79 (0.38 to 1.64) NA
 Antepartum death 8 (0.1) 9 (0.2)
 Intrapartum death 1 (0) 0 (0)
 Neonatal death, 0-7 days postnatal 5 (0.1) 6 (0.1)
Apgar score <4 at five minutes 13 039 7066, 21 (0.3) 5976, 27 (0.5) 0.66 (0.37 to 1.16) NA
Impaired consciousness 12 995 7040, 7 (0.1) 5955, 9 (0.2) 0.66 (0.25 to 1.77) NA
Asphyxia (cord blood arterial base excess ≤12 mmol/L) 13 012 7047, 74 (1.1) 5965, 70 (1.2) 0.89 (0.64 to 1.24) 0.88 (0.62 to 1.23)
Seizures on ≥2 occasions <72 hours after birth 12 997 7041, 6 (0.1) 5956, 6 (0.1) 0.85 (0.27 to 2.62) NA
Assisted ventilation >24 hours by endotracheal tube <72 hours after birth 12 997 7040, 27 (0.4) 5957, 19 (0.3) 1.20 (0.67 to 2.17) NA
Septicaemia ascertained by blood culture 12 997 7041, 7 (0.1) 5956, 4 (0.1) 1.48 (0.43 to 5.06) NA
Meningitis ascertained by cerebrospinal fluid culture 12 997 7041, 1 (0) 5956, 2 (0) 0.60 NA
Bronchopulmonary dysplasia: need for oxygen ≥36 weeks’ gestational age, 
confirmed by radiography
12 997 7041, 0 (0) 5956, 1 (0) 0.46 NA
Intraventricular haemorrhage grade 3 or 4, confirmed by ultrasonography/
autopsy
12 995 7041, 0 (0) 5954, 1 (0) 0.46 NA
Cystic periventricular leucomalacia, confirmed by ultrasonography/autopsy 12 997 7041, 0 (0) 5956, 0 (0) NA NA
Necrotising enterocolitis, confirmed by radiography/surgery/autopsy 12 997 7041, 1 (0) 5956, 1 (0) NA NA
Secondary neonatal outcome
Mean (SD) birth weight (g) 13 035 7065, 3478 (518) 5970, 3487 (511) 0.35 −1.75 (−20.3 to 16.8)
SGA at birth 13 007 7046, 572 (8.1) 5961, 447 (7.5) 1.09 (0.96 to 1.24) 1.03 (0.90 to 1.18)
LGA at birth 13 007 7046, 748 (10.6) 5961, 640 (10.7) 0.99 (0.88 to 1.10) 0.98 (0.87 to 1.10)
Mean (SD) gestational age at birth (weeks) 13 043 7066, 39.7 (1.61) 5977, 39.7 (1.57) 0.98 0.02 (−0.04 to 0.07)
Prematurity (<37 weeks): 13 043 7066, 283 (4.0) 5977, 251 (4.2) 0.95 (0.80 to 1.13) 0.93 (0.77 to 1.12)
 32-37 weeks 249 (3.5) 225 (3.8)
 <32 weeks 34 (0.5) 26 (0.4)
Neonatal death, 8-28 days after birth¶ 1520 759, 1 (0.1) 761, 1 (0.1) NA NA
Detection of congenital abnormalities 13 038 7062, 167 (2.4) 5976, 117 (2.0) 1.21 (0.96 to 1.54) 0.97 (0.74 to 1.26)
Presented outcome variables were prespecified in the Netherlands Trial Registry (NTR4367).
NA=not applicable (numbers too small); SGA=small for gestational age (birth weight <10th centile (<P10) of Dutch (Perined) birth weight curve27); LGA=large for gestational age (birth weight 
>P90 of Dutch (Perined) birth weight curve27).
*Numbers differ because of missing values. 
†P values based on independent t tests for continuous outcome variables and Fisher’s exact tests for categorical variables because of empty cells or expected cell counts <5.
‡Adjusted odds ratios and 95% confidence intervals were calculated by multilevel, multivariable logistic regression adjusted for clustering and for potential confounders, including maternal age; 
body mass index; smoking, alcohol, or recreational drug use; and midwifery practice size; parity; educational level; employment status; marital status; and sex of infant. In the various multilevel, 
multivariable models, the amount of missing values for potential confounders was ≤4.4%.
§One or more of perinatal death, Apgar score <4 at five minutes, impaired consciousness, asphyxia, seizures, >24 hour assisted ventilation, haemorrhage; meningitis, bronchopulmonary 
dysplasia, intraventricular haemorrhage, cystic periventricular leucomalacia, or necrotising enterocolitis.
¶Information based only on hospital records.
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showed an increase in identifying the risk of stillbirth 
when customised fetal growth charts were used.38 
Nonetheless, in the prospective POP study, compared 
with universal charts, customised charts did not 
result in an increased association between estimated 
fetal weight below the 10th centile and neonatal 
morbidity.11 Before the start of our study, the Royal 
Dutch Association of Midwives issued guidelines on 
fetal growth restriction and recommended customised 
fetal growth curves. Technical difficulties prevented 
integration of this approach into many midwifery 
practices, whereas hospitals did not use customised 
curves. The applied multidisciplinary protocol 
therefore recommended serial measurements of fundal 
height but not plotting them on customised growth 
curves.
Even if birth weight can be estimated accurately, 
many small babies are constitutionally small but 
healthy.11 In the POP study, about 70% of fetuses 
with an estimated fetal weight below the 10th centile 
were not growth restricted and had similar perinatal 
outcomes compared to those with a greater estimated 
fetal weight.11 Disadvantages associated with routine 
ultrasound scans in the third trimester might be 
increased levels of emotional distress in women because 
of an inaccurate suspicion of fetal growth restriction 
and increased exposure to additional diagnostic tests, 
monitoring, and obstetric interventions.39 40 That 
the incidence of most obstetric interventions was not 
significantly different between the groups is reassuring 
but we found a higher incidence of induction of labour 
associated with the intervention strategy, with no 
evidence of better perinatal outcomes. A study also 
showed that a suspicion of SGA was associated with a 
higher incidence of initiated delivery by the provider.9 
The incidence of augmentation of labour was lower in 
the intervention strategy. Oxytocin would, however, 
have been used as part of the induction of labour 
strategy but this would not have been recorded 
separately in the Perined database. Inducing labour 
artificially is more invasive than augmentation of 
labour that has started spontaneously, and overuse of 
induction of labour in the absence of clear beneficial 
effects is a growing concern.41 42 Overall, the findings 
of this pragmatic trial do not support a policy of routine 
ultrasound screening in the third trimester for low risk 
pregnant women to reduce severe adverse perinatal 
outcomes.
As estimated fetal weight and abdominal 
circumference alone are not good markers of fetal 
growth restriction, more sensitive methods are 
needed. These include other ultrasound markers of 
fetal compromise, such as Doppler indices.18 The POP 
study showed that the combination of ultrasonography 
in the third trimester and measurement of placental 
biomarkers in the mother’s blood (the soluble fms-
like tyrosine kinase 1:placental growth factor ratio) 
strongly predicted adverse pregnancy outcomes related 
to fetal growth restriction, suggesting that biomarkers 
might be useful in detecting growth restriction.43 
Moreover, women are aware of fetal movements, which 
are a sign of fetal wellbeing. A change in fetal activity 
Table 5 | Maternal outcomes and peripartum interventions
Maternal outcomes and peripartum interventions Total No*
No, No of events (%) Odds ratio (95% CI) or 
P value
Adjusted odds ratio 
(95% CI)†Intervention strategy Control strategy
Peripartum interventions and mode of delivery
Composite of spontaneous vaginal birth without intervention‡ 12 490 6663, 2974 (44.6) 5827, 2650 (45.5) 0.97 (0.90 to 1.04) 1.00 (0.92 to 1.08)
Induction of labour§ 12 984 7034, 1118 (15.9) 5950, 813 (13.7) 1.19 (1.08 to 1.32) 1.16 (1.04 to 1.30)
Vacuum or forceps assisted birth 13 044 7065, 538 (7.6) 5979, 506 (8.5) 0.89 (0.79 to 1.01) 0.90 (0.78 to 1.04)
Caesarean section: 13 044 7065 5979 1.01 (0.91 to 1.12) 1.00 (0.90 to 1.11)
 Primary 414 (5.9) 342 (5.7)
 Secondary 555 (7.9) 472 (7.9)
 Total 969 (13.7) 814 (13.6)
Augmentation of labour 12 713 6894, 1902 (27.6) 5819, 1839 (31.6) 0.82 (0.76 to 0.89) 0.78 (0.71 to 0.85)
Pharmacological pain relief 12 337 6582, 2786 (42.3) 5755, 2378 (41.3) 1.04 (0.97 to 1.12) 1.02 (0.94 to 1.11)
Maternal peripartum morbidity and mortality
Composite outcome of maternal morbidity/mortality¶ 11 787 6327, 1123 (17.7) 5460, 910 (16.7) 1.08 (0.98 to 1.19) 1.06 (0.95 to 1.18)
Maternal death, up to 42 days after birth 13 044 7065, 0 (0) 5979, 0 (0) NA NA
Hypertensive disorders 11 638 6235, 539 (8.6) 5403, 445 (8.2) 1.05 (0.93 to 1.20) 1.06 (0.91; 1.22)
Postpartum haemorrhage 13 044 7065, 472 (6.7) 5979, 402 (6.7) 0.99 (0.87 to 1.14) 0.98 (0.85 to 1.14)
Third or fourth degree perineal trauma 13 044 7065, 186 (2.6) 5979, 134 (2.2) 1.18 (0.94 to 1.48) 1.17 (0.92 to 1.47)
Other secondary maternal outcomes
Birth in obstetrician led care 13 018 7047, 4580 (65.0) 5971, 3778 (63.3) 1.08 (1.00 to 1.16) 1.05 (0.96 to 1.14)
Non-cephalic presentation at start of labour 12 922 6998, 203 (2.9) 5924, 198 (3.3) 0.86 (0.71 to 1.05) 0.87 (0.71 to 1.07)
Presented outcome variables were prespecified in the Netherlands Trial Registry (NTR4367) except for hypertension and pre-eclampsia, which were combined into one variable—that is, 
hypertensive disorders were defined as a diastolic blood pressure ≥95 mm Hg with or without proteinuria or ≥90 mm Hg with proteinuria, because of the small number of cases (n=12) with 
proteinuria and diastolic blood pressure ≥90 mm Hg.
NA=not applicable (numbers were too small).
*Total numbers differ because of missing values. 
†Adjusted odds ratios and 95% confidence intervals were calculated by multilevel, multivariable logistic regression adjusted for clustering, midwifery practice size (potential fixed factor), and 
potential confounders, including maternal age; body mass index; smoking, alcohol, or recreational drug use; parity; educational level; employment status; marital status; sex of infant; and 
midwifery practice size. In the various multilevel, multivariable models, the amount of missing values for potential confounders was ≤4.4%.
‡Defined as spontaneous vaginal birth, without induction or augmentation of labour, and with no drug pain relief, vacuum or forceps assisted birth, or caesarean section.
§Based on available data (n=12 971) for both induction of labour and prematurity status, labour was induced in 12% (n=33) of 283 premature infants in the intervention strategy and 12% 
(n=29) of 251 premature infants in the control strategy.
¶Composite outcome was one or more of maternal peripartum death within 42 days after delivery, maternal hypertension (with or without proteinuria), postpartum haemorrhage, and third or 
fourth degree perineal trauma.
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might be a sign of fetal growth restriction.44 Fetal 
death, often associated with fetal growth restriction, 
is usually preceded by reduced fetal movements.44 
More research is needed, however, to determine what 
type of information women should receive about 
the wellbeing of the fetus.44 Further research is also 
needed to address the histopathological mechanisms 
that might underlie the association between fetal 
growth restriction and perinatal death, including 
sudden intrauterine unexplained death, and to 
improve preventive strategies.45 46
Strengths and limitations of this study
Our study has strengths and limitations. The 
cluster randomised design controlled for unknown 
confounders at the cluster level and limited 
contamination between the study strategies, which 
might occur in individual randomised trials. The 
stepped wedge design reduced confounding owing to 
differences between midwifery practices because each 
practice applied the control and intervention strategy 
for some of the time. Sonographers met predefined 
quality criteria, and a multidisciplinary protocol was 
developed for detecting and managing fetal growth 
restriction to achieve the best quality care possible in 
a pragmatic nationwide study.13 20
We did not achieve our required sample size of 
15 000 women. Owing to the stepped wedge design, it 
was not possible to extend the data collection period 
because the midwifery practices had adopted the 
intervention strategy at the end of the study period. 
We cannot therefore completely rule out that the study 
lacked the statistical power to determine if routine 
ultrasonography has a beneficial or harmful effect 
on perinatal outcomes compared with usual care. 
Although we found a difference of only 0.1% between 
the two strategies, it is unlikely that this difference 
would have met the preset meaningful difference of 
0.54% had the sample size been larger. Also, we used 
registration data as an initial screening for potential 
severe adverse perinatal outcomes. Information 
was also obtained from many hospital records, but 
for most women only routine registration data for 
adverse outcomes were available. Because of the 
inherent limitations of these data, several outcomes 
might have been misclassified as normal, resulting 
in an underestimation of the primary outcome for 
both strategies. But we do not expect that this has 
biased the comparison between the two strategies as 
the incidence of adverse outcomes was similar to our 
estimations. Furthermore, because of the collinearity 
of time of inclusion period and study condition, we 
were unable to adjust for time. The effect estimates of 
our main analyses might therefore be overestimated. 
Finally, our study was conducted in one country 
(the Netherlands) where primary antenatal care of 
uncomplicated pregnancies is provided by midwives 
who are educated, trained, and officially registered 
as independent health practitioners.21 When risk 
factors or complications occur, women are referred to 
obstetrician led care. For about 90% of women in the 
Netherlands, antenatal care is midwife led initially, 
and about 50% of women start labour in midwife 
led care.26 Also, most of the recommendations of 
the multidisciplinary protocol for diagnosing and 
managing suspected fetal growth restriction in our 
study are similar to international guidelines in other 
countries (eg, the Royal College of Obstetricians and 
Gynaecologist),25 making our results relevant to low 
risk populations in other international care contexts.
Conclusions
Our pragmatic nationwide trial found that routine 
ultrasonography in the third trimester of pregnancy 
and with a multidisciplinary protocol for detecting 
and treating fetal growth restriction was associated 
with a moderately increased antenatal detection of 
SGA neonates and induction of labour. This strategy 
was not, however, associated with a reduction in 
the incidence of severe adverse perinatal outcomes 
in low risk pregnancies compared with usual care 
including clinically indicated ultrasonography. Based 
on our findings, we cannot recommend routine 
ultrasonography in the third trimester in low risk 
pregnancies. Challenges for future research are to 
identify the most appropriate fetal growth and birth 
weight charts and to develop more sensitive and 
effective methods to detect fetal growth restriction. 
Such methods include other ultrasound markers of 
fetal compromise, maternal and placental biomarkers, 
and maternal awareness of fetal wellbeing.
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